No Data
No Data
Grifols' Biotest Set to Launch Intravenous Immunoglobulin in US in Q1 2025
Grifols' (GRF.MC) Biotest will launch its intravenous immunoglobulin Yimmugo in the US in the first quarter of 2025 after receiving US Food and Drug Administration approval for the treatment of primar
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025Yimmugo will be distributed by Kedrion in the U.S. as part
Grifols Says At End June 2024, Considering SRAAS Proceeds, Leverage Ratio Is Expected To Reach 5.4x Vs. 6.8x In March 2024; FCF In Q2 2024 Expected To Be Positive, Contributing To Reach €5 Million FY24 Guidance, Which Includes €480 Million Of...
Grifols Says At End June 2024, Considering SRAAS Proceeds, Leverage Ratio Is Expected To Reach 5.4x Vs. 6.8x In March 2024; FCF In Q2 2024 Expected To Be Positive, Contributing To Reach €5 Million FY2
Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured Notes And 2027 Term Loan B And On A Pro-Rata Basis...
Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.27% to 1,423.98 on the S&P Europe Select ADR Index. From continental Europe, the gainers
Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value